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Core outcome sets (COSs) are consensus-derived minimum sets of outcomes to be assessed in a specific
situation. COSs are being increasingly developed to limit outcome-reporting bias, allow comparisons across
trials, and strengthen clinical decision making. Despite the increasing interest in outcomes research, methods to
develop COSs have not yet been standardized. The aim of this paper is to present the Harmonizing Outcomes
Measures for Eczema (HOME) roadmap for the development and implementation of COSs, which was developed
on the basis of our experience in the standardization of outcome measurements for atopic eczema. Following the
establishment of a panel representing all relevant stakeholders and a research team experienced in outcomes
research, the scope and setting of the core set should be defined. The next steps are the definition of a core set
of outcome domains such as symptoms or quality of life, followed by the identification or development and
validation of appropriate outcome measurement instruments to measure these core domains. Finally, the
consented COS needs to be disseminated, implemented, and reviewed. We believe that the HOME roadmap is a
useful methodological framework to develop COSs in dermatology, with the ultimate goal of better decision
making and promoting patient-centered health care.
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INTRODUCTION
Measurement has a central role in med-
icine. In everyday clinical practice we
examine patients in order to diagnose,
provide a prognosis, and monitor
change over time. In clinical trials, out-
come measurements are used to assess
the safety and efficacy of the interven-
tions being investigated. Researchers
may choose from a great variety of
different outcome measurements to use
as primary and secondary end points in
clinical trials. However, comparing data
and pooling of clinical trial results in
systematic reviews and for guideline
development can only be carried out if
the underlying clinical trials use the
same outcome measurements.
In atopic eczema, we have previously
identified more than 20 named mea-
surement instruments to assess disease
severity in clinical trials (Schmitt et al.,
2007a). Because these instruments differ
in the items and domains they include
and because most instruments have not
been sufficiently validated (Schmitt
et al., 2013), treatment effects cannot
be readily compared and meta-analyses
are difficult, if not impossible (Schmitt
et al., 2007b). This situation is a signi-
ficant threat to evidence-based health
care, as clinical decision making
depends on the summary of the best
evidence available to balance the harms
and benefits of treatments and therefore
the comparability of trial data.
The global, multi-professional
Harmonizing Outcome Measures for
Eczema (HOME) initiative is an evi-
dence-driven and evidence-generating
outcomes research initiative that aims
to standardize and validate a core set of
outcome measurements for atopic
eczema and increase the quality of out-
comes research in dermatology (Schmitt
and Williams, 2010; Schmitt et al.,
2012; Schram et al., 2012; Schmitt
et al., 2013).
Despite the increasing significance of
outcomes research and the development
of core outcome sets (COSs), the
methods to develop and implement
COSs have not yet been standardized
(Williamson et al., 2012).
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Influenced by, and in cooperation
with, other international outcomes re-
search groups such as the Outcome
Measures in Rheumatology (Tugwell
et al., 2007), the Core Outcome
Measures in Effectiveness Trials
(COMET) (Sinha et al., 2008), and the
Consensus-based Standards for the
Selection of Health Measurement
Instruments (COSMIN; (Mokkink et al.,
2010b) initiatives, the members of the
HOME executive board (the authors of
this article) have developed a systematic
process for developing a core set of
outcome measurements. We believe
that the HOME roadmap may serve as
a methodological standard for develop-
ing COSs for other (skin) diseases such as
skin cancer, psoriasis, acne, hand
eczema, and chronic wounds.
As the research field of outcome
domains and measures is developing,
the HOME roadmap may evolve as new
important developments emerge in the
field. Core sets of outcome measure-
ments reflect the best evidence at a time
and can be revised or modified in light
of new evidence.
THE CONCEPT OF COSs
A COS is a consensus-derived minimum
set of outcomes to be assessed in a
specific situation in clinical research or
clinical care. The concept of COSs has
been developed to standardize out-
comes across trials to allow comparisons
of the results of different trials in a given
condition (Kirkham et al., 2013b). A core
outcome can be included as a primary
or a secondary outcome. Many more
outcomes can be measured in addition
to the core outcomes as indicated in
Figure 1. In rheumatology, the Outcome
Measures in Rheumatology group has
over 20 years of experience in develop-
ing COSs (Tugwell and Boers, 1993),
and the majority of trials in rheumatoid
arthritis now include the COS (Kirkham
et al., 2013a). This example indicates
that COSs have the potential to
standardize and improve clinical trial
methodology and thus improve the
overall quality of the evidence base for
health-care decision making.
Two different levels of COSs need to
be differentiated––core sets of outcome
domains and core sets of outcome
measurement instruments (Table 1).
Core sets of outcome domains
(concepts to be measured) constitute
an agreed minimum set of outcome
domains to be measured. Outcome
domains are aspects of disease, such as
health-related quality of life, symptoms,
clinical signs, productivity loss, or dis-
ability. Outcome domains relate to
‘‘what’’ should be measured. The aim
of a core set of outcome domains is to
consistently assess the essential features
or aspects of health for a given
condition.
Core sets of outcome measurement
instruments constitute an agreed set of
measurement instruments to assess the
core outcome domains. Outcome mea-
surements relate to ‘‘how’’ to measure
an outcome domain (measurement
method, items, and quantification of
response). In dermatology, examples of
outcome measurement instruments fre-
quently used for assessing clinical signs
(domain) include the Psoriasis Area
Severity Index for psoriasis and the
Eczema Area Severity Index (EASI) or
the objective Scoring Atopic Dermatitis
index for atopic eczema. To meet the
requirements of evidence-based health
care, outcome measurement instruments
need to be valid, reliable, and sensitive
to change and should also be feasible
in their application (Mokkink et al.,
2010b).
THE HOME ROADMAP
The development of a core set of out-
come measurements requires an inte-
grated process of systematic reviews,
consensus studies, validation studies,
and consensus voting. The team to
develop a core set of outcome measure-
ments should include all relevant stake-
holders (Williamson et al., 2012) and
should include researchers with exper-
ience in both qualitative and quanti-
tative outcomes research. Following
the HOME roadmap, the development
of a core set of outcome measurements
consists of a four-step process (Figure 2).
Step 1: Define scope and applicability
The first step in the development of a
core set of outcome measurement
instruments is to define its scope and
applicability. This includes the popula-
tion (i.e., disease or stage of disease), the
setting (e.g., trial, record keeping, clin-
ical registry, and quality assurance), and
the geographical scope. All relevant
Figure 1. The concept of core outcome sets. The large blue circle symbolizes all outcome domains/
measures that may be used. The small red circle symbolizes the core set of outcome domains/measures.
The core outcome domains/measures constitute a consensus-derived evidence-based minimum set of
domains/measures to be assessed. It is important that all investigators include the core outcome set to allow
comparisons of the results of different trials. A core outcome domain/measure can be included as a primary
or a secondary outcome.
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stakeholder groups should be involved
throughout the entire developmental
process. For clinical trials we deter-
mined patients, health-care profes-
sionals, researchers, regulatory agen-
cies, and pharmaceutical companies to
be relevant stakeholders. We recom-
mend keeping core outcome initiatives
open to all interested parties, in order to
form a diverse group in terms of view-
points and talents. At least for COSs for
trials the global perspective should be
captured by involving stakeholders from
all over the world. To achieve truly
global representation of patients and
health-care professionals, proactive
approaches and possibly funding to
enable participation in consensus meet-
ings may be necessary.
Step 2: Define core set of outcome
domains
The second step is the development of a
core set of outcome domains by means
of a consensus study. The Delphi
method and the nominal group techni-
que have been successfully applied to
define COSs (Idzerda et al., 2014;
Schmitt et al., 2011). The consensus
study should be based on an a priori
protocol. The protocol should include
consensus rules, i.e., minimum require-
ments for a consensus within the panel.
The HOME group defined that a
consensus is reached if less than 30%
of the voters disagree (Schmitt et al.,
Step 1: Define scope and applicability
Step 2: Develop core set of outcome domains
Step 3: Develop core set of outcome measurements
Step 4: Disseminate, prepare guidance
material, review, and possibly revise core set
of outcome measurements
Population (condition)
Intervention
Setting (e.g., trial, registry, clinical practice)
Geographical/regional scope*
Stakeholders
Consensus study involving representatives of
relevant stakeholders
Identification and recommendation of adequate measurement instrument(s) for each core
outcome domain by a 5-stage process
Stage 1
Identify all
instruments
previously
used to
measure the
domain.
Systematic
review of
outcome
instruments
used.
Ta
sk
M
et
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do
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gy
O
ut
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t
Systematic
review of
validation
studies of the
long-list of
identified
instruments.
Highlight any
gaps in
validation.
Establish the
extent and
quality of
testing of the
identified
instruments.
Determine which instruments are good enough quality and meet
the requirements of the OMERACT filter and be shortlisted
for further consideration.
Apply OMERACT filter; truth, discrimination, and feasibility:
“Is the measure
truthful, does it
measure what it
intends to
measure? Is the
result unbiased
and relevant?”
Consensus
discussion and
voting on truth:
Consensus discussion
and voting on
discrimination:
Consensus
discussion and
voting on feasibility:
1. Face validity
2. Content validity
3. Construct
    validity
4. Criterion validity
Long list of
all
instruments
previously
used to
measure the
domain.
Summary of
which
instruments
have been
tested and
the quality,
extent, and
results of any
testing.
Short-list of potential instruments that meet the
requirements of the OMERACT filter.
1. Reliability
2. Sensitivity to
    change
1. Time take
2. Cost
3. Interpretability
Short list of
fully tested
instruments.
Recommended
core outcome
instrument for
the domain.
Discrimination Feasibility
Consensus
discussion and
voting to
determine what
validation
studies will be
conducted on
short-listed
instruments.
Gaps in testing
were highlighted
in stage 2
(systematic
review).
Appropriate
methods used to
fill the gaps in
validation.
Reapply the
OMERACT filter
with the results
of the completed
validation
studies.
Carry out
validation
studies on
shortlisted
scales.
Finalize of core
outcome
instrument for
domain.
Stage 2 Stage 3 Stage 4 Stage 5
Consensus
discussion and
voting on core
outcome to be
recommended.
Truth
“Does the measure
discriminate
between situation
that are of interest?”
“Can the measure
be applied easily
in it’s intended
setting, given
constraints of
time, money, and
interpretability?”
Figure 2. The Harmonizing Outcome Measures for Eczema (HOME) roadmap to develop core sets of outcome measurement instruments. *For trials the scope
should generally be global.
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2012). The consensus panel should
reflect the scope and applicability of
the core set to be developed. Gene-
rally, as a minimum, patients (or their
representatives), clinical researchers, and
relevant clinicians should be considered
as key stakeholders. Additional stake-
holder groups such as regulatory
authorities, industry, and health policy
representatives may also be considered.
The application of consensus methods
such as the Delphi method or the
nominal group technique is necessary
to avoid dominance of individual panel
members. For the same reason, it is
useful to engage a moderator with exper-
ience in consensus studies to provide an
independent oversight. Any consensus
process needs to be based on evidence
to inform decisions. Typically, a consen-
sus process includes reviews, surveys,
small group discussions, plenary discuss-
ions, and confidential voting at face-to-
face meetings (Schmitt et al., 2012).
Step 3: Define core set of outcome
measurements: identify, validate, or
develop an appropriate measurement
instrument for each core outcome
domain
The identification of appropriate instru-
ments for each core outcome domain
involves five stages. Ideally, one best
instrument should be defined for each
core outcome domain.
 Stage 1: All measurement instruments
previously used to assess the domain
in the setting of interest need to be
identified using a systematic review
methodology.
 Stage 2: For each outcome measure-
ment instrument included in the list of
possible outcome measurements, the
extent and quality of testing and the
measurement properties of the instru-
ments need to be determined by
means of a systematic review. Three
important measurement properties
that need to be assessed are validity
(the degree to which an instrument
measures the construct(s) it purports to
measure), reliability (the degree to
which the measurement is free from
measurement error), and responsive-
ness to change (the ability of an
instrument to detect change over time
in the construct to be measured;
Mokkink et al., 2010b). A fourth
domain that also needs to be
assessed is ‘‘interpretability’’—that is,
the degree to which one can assign
qualitative meaning to quantitative
scores (Boers et al., 1998). Interpre-
tability is not considered a measure-
ment property but is nevertheless an
important characteristic of measure-
ment instruments. Interpretability en-
compasses examining the assessment
of floor and ceiling effects as well as
the minimal important change and
clinical bandings according to the
overall severity of disease.
Various criteria have been proposed
to assess outcome measurement instru-
ments. For instance, COSMIN initiative
(www.cosmin.nl) has proposed quality
criteria for measurement properties of
health status questionnaires, in particu-
lar patient-reported outcomes (Terwee
et al., 2007; Mokkink et al., 2010b).
COSMIN also developed a checklist for
the assessment of the quality of vali-
dation studies (the COSMIN checklist)
and sensitive search terms for systematic
reviews of validation studies that we
recommend (Mokkink et al., 2010a).
 Stage 3: The systematic review of
measurement properties (stage 2) is
used to inform the consensus process
whether or not the individual outcome
measurement instruments are suitable
to assess the core outcome domain.
All relevant stakeholders should be
involved. Within the HOME initiative,
we reached a broad international
consensus among health-care profes-
sionals, patients, and clinical resear-
chers that the Outcome Measures in
Rheumatology-filter of ‘‘Truth, Discri-
mination, and Feasibility’’ (Boers
et al., 1998) should be met for out-
come measurements to be recommen-
ded (Schmitt et al., 2012). ‘‘Truth’’
means that the outcome measure-
ment captures what it intends to, and
thus corresponds to the measurement
property ‘‘validity’’. ‘‘Discrimination’’
means that the outcome measure-
ment discriminates between disease
states in a reliable way, and there-
fore corresponds to the measure-
ment criteria of ‘‘reliability’’ and
‘‘sensitivity to change’’. ‘‘Feasibility’’
captures important aspects of outcome
Table 1. The two levels of core outcome sets: the concepts of core outcome domains and core outcome
measurement instruments
Core set of outcome domains Core set of outcome measurement instruments
Definition
Domain: Outcome measurement instrument:
The concept to measure Measurement method, items, and quantification of response
The ‘‘what’’ to measure The ‘‘how’’ to measure the domain
Example: clinical signs of atopic eczema Example: the Eczema Area and Severity Index (EASI)
Core set of outcome domains: Core set of outcome measurement instruments:
Minimum set of outcome domains that should be assessed Minimum set of outcome measurement instruments that should be assessed
Requirements
Involvement of all relevant stakeholder groups Involvement of all relevant stakeholder groups
Based on external evidence/systematic review and/or conceptual framework Based on external evidence/systematic review
Developed by consensus study following an a priori protocol Outcome measurement instruments should meet the requirements of validity, reliability,
sensitivity to change, and feasibility
Developed by consensus study following an a priori protocol
J Schmitt et al.
The HOME Roadmap
www.jidonline.org 27
measurements beyond the classic
psychometric properties such as
interpretability (see above stage 2),
cost, availability, time requirements,
and practicability and clearly depends
on the setting (Boers et al., 1998). The
output of stage 3 is a short list of
instruments that may be considered as
potential core outcome measurement
instruments (Figure 2).
 Stage 4: The absence of evidence on
measurement properties does not
mean that a measurement instrument
is inadequate. Depending on the
results of stages 2 and 3, validation
studies of outcome measurement
instruments included in the short list
may be necessary to clarify whether or
not outcome measurement instru-
ments meet the requirements of
‘‘Truth, Discrimination, and Feasibil-
ity’’ (Boers et al., 1998). It may be
necessary, or preferable, to develop a
new instrument if existing measure-
ment instruments are found to be
inadequate. If one or more suitable
measurement instruments have been
identified then stage 4 is not
necessary.
 Stage 5: The evidence from the vali-
dation studies (stage 4) and the results
of the systematic review on measure-
ment properties (stage 2) inform a
consensus process on whether or not
the individual measurement instru-
ments are suitable to assess the core
outcome domain. Finally, consensus
voting involving the relevant stake-
holder groups (please refer to step 2)
determines whether or not a specific
measurement instrument is included
in the core set of outcome measure-
ments.
Stages 1–5 need to be completed for
each core outcome domain. Once an
outcome measurement instrument has
been recommended for each core out-
come domain, the core set of outcome
measurement instruments is complete.
Step 4: Dissemination, preparation of
guidance material, review, and possibly
revision of the core set of outcome
measurement instruments
The dissemination and implementation
of the core set of outcome measure-
ments are of utmost importance. The
goal is that all stakeholders in the target
field and area comply with it. Therefore,
dissemination should involve publica-
tions in leading journals (e.g., by con-
sensus statements, supplemented by
editorials and/or commentaries), presen-
tations at relevant meetings, and disse-
mination to journal editors and
reviewers as well as to all other relevant
stakeholders. Core sets of outcome mea-
surements for clinical trials should also
be disseminated to the pharmaceutical
industry and to regulatory authorities.
The development of guidance material
is recommended to facilitate dissemina-
tion and application of the COS. Gui-
dance material may include training
manuals on instrument use, guidance
on interpretation of scores and what
constitutes a minimal important clinical
change, summaries of the distribution of
scores in different populations to inform
sample size calculations, and sugges-
tions for the presentation of study
results.
The use of the recommended core set
of outcome measurements should be
monitored to be able to detect possible
barriers to the implementation and to
optimize the implementation strategy.
Core sets of outcome measurements
reflect the best evidence at the time
and can be revised or modified in light
of new evidence. Any revision or mod-
ification should be carried out by con-
sensus in accordance with the methods
outlined in the HOME roadmap
(Figure 2).
DISCUSSION
Failure to assess the most important
aspects of a disease and the use of
outcome measurement instruments with
unclear validity or reliability have been
increasingly recognized as important
barriers toward practicing evidence-
based medicine (Chalmers and
Glasziou, 2009). This has led to the
development of COSs in various fields
of medicine over the past years (Ruperto
et al., 2003; Taylor, 2005; Schmitt et al.,
2011).
Despite the increasing interest in out-
comes research and the broad recogni-
tion of the benefits of COSs (Tugwell
et al., 2007; Mokkink et al., 2010b;
Sinha et al., 2012; Idzerda et al., 2014;
Macefield et al., 2014), general
guidance on how to develop a COS is
still missing. The HOME roadmap pro-
vides this guidance and was developed
through our experience in atopic
eczema outcomes research. We
believe that this roadmap is widely
applicable to the development of COSs
for all (skin) diseases and hope that
others performing outcomes research
will benefit from our experiences.
The development of evidence-based
core sets of outcome measurements for
clinical trials, clinical registries, record
keeping, and quality assurance in rou-
tine care is a major task and requires
significant resources and a multi-profes-
sional team of health-care professionals,
patient representatives, and clinical
researchers. On the basis of our experi-
ence, the development of a core set of
outcome measurement instruments in
accordance with the HOME roadmap
requires many years of work. Encour-
aged by a systematic review on named
outcome measurements for atopic
eczema (Schmitt et al., 2007a), and a
preliminary Delphi consensus study
(Schmitt et al., 2011), the HOME
initiative was founded in 2010 as a
global multi-professional evidence-
driven and evidence-generating initia-
tive dedicated to outcomes research in
atopic eczema (Schmitt and Williams,
2010). After the definition of the core set
of outcome domains for atopic eczema
trials in 2011 consisting of clinical signs,
symptoms, quality of life, and long-term
control of flares, we established a
working group for each of these core
outcome domains to identify appro-
priate measurement instruments
(Schmitt et al., 2012). Following the
HOME roadmap we completed the
selection of the core outcome measure-
ment instrument for the domain clinical
signs in 2013. Systematic reviews
indicated that from various different
instruments to quantify the severity of
clinical signs of atopic eczema only the
EASI and the objective Scoring Atopic
Dermatitis Index fulfill the criteria to be
included in the list of possible
instruments (Schmitt et al., 2013). In an
international consensus study, 56 indivi-
duals from 10 countries including Asia,
Europe, South America, and the United
States representing stakeholders such
as consumers, dermatologists, nurses,
J Schmitt et al.
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clinical researchers, methodologists,
and pharmaceutical industry represen-
tatives agreed that EASI is the preferred
core instrument to measure clinical
signs in future atopic eczema trials.
Details of the meeting and consensus
process can be found elsewhere
(Chalmers et al., 2014). The selection
of core outcome measurement
instruments for the domains of quality
of life, symptoms, and long-term control
of atopic eczema flares is ongoing
(www.homeforeczema.org).
Important outcomes research groups
with focus on COSs and clinimetric
properties of measurement instruments
are the COMET and the COSMIN initia-
tives. The COMET initiative provides a
database of planned, ongoing, and com-
pleted core sets of outcome domains for
clinical trials and makes this information
accessible (www.cometinitiative.org).
The COSMIN initiative provides criteria
to assess the quality of validation studies
(Mokkink et al., 2010a), guidance on
systematic reviews on measurement
properties (de Vet et al., 2011), and
consented definitions of these
measurement properties (Mokkink
et al., 2010b). The HOME initiative is
represented in the Core Outcome
Measures in Effectiveness Trials
database and applied the definitions
and guidance material on systematic
reviews on measurement properties
developed by the COSMIN group.
COSs do not preclude the use of other
measures of interest to investigators but
identify the minimum standard that
should be present in all studies. They
should be based on the best evidence
available at the time of consensus agree-
ment but can be revised in the light of
new evidence or developments.
COSs have been introduced in clin-
ical trials to minimize selective
outcome–reporting bias, to increase
clinical interpretability, and to enable
valid pooling of results across studies.
The majority of the coordinating editors
of the Cochrane Review Groups indi-
cated that a COS for effectiveness trials
should be used routinely for a Summary
of Finding table in their Cochrane
Reviews (Kirkham et al., 2013b).
Funding bodies are increasingly asking
for COSs to be included in the trial-
funding applications (e.g., this is now a
requirement for the National Institute for
Health Research Health Technology
Assessment programme in the United
Kingdom (http://www.nets.nihr.ac.uk/
programmes/hta).
To date, COSs have been almost
exclusively developed to standardize
outcome assessment across clinical
trials in a specific condition. However,
the concept of COSs may also be
applied in other settings such as record
keeping, observational studies, clinical
registries, or quality assurance in health
care. Ideally, similar outcomes should
be assessed in trials and in daily practice
to enable the translation of trial
evidence into clinical care (Schmitt
et al., 2011).
In dermatology, a lot of work has
been carried out to develop new instru-
ments for the assessment of different
aspects of skin disorders. However,
many of the existing outcome measure-
ment instruments in dermatology have
not been validated appropriately, and
through their application we may under-
estimate, overestimate, or completely
miss the true effects of an intervention
(Spuls et al., 2009; Nijsten, 2012;
Vrijman et al., 2012; Schmitt et al.,
2013). General, overarching studies to
define which aspects of skin disorders
are of such importance that they should
be regularly assessed by means of
defined, suitable instruments in every
trial or other study are still very scarce in
dermatology. Investigators should
therefore focus more on the develop-
ment of COSs and develop new out-
come measurement instruments prefe-
rably in the context of multi-stakeholder
and multi-perspective outcomes
research initiatives. Another example
from dermatology concerning the
development of a core set of outcome
measures is vitiligo. Following a
systematic review of existing out-
come measures for vitiligo and a
survey of the most important out-
comes for patients and clinicians
(Eleftheriadou et al., 2012), a Delphi
study has been conducted to define a
core set of outcome domains for vitiligo
trials.
We encourage investigators and
advocates from various fields within
dermatology to pursue the development
of COSs. For many other skin diseases
with multiple and disparate outcome
measures, such as psoriasis, acne, skin
cancer, chronic wounds, and hand
eczema, a core set of outcome measure-
ment instruments is required, and we
hope that the HOME roadmap will serve
as guidance in this process.
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